Innovative CPAP Product From Australia

Sleep Apnea **

http://www.sleepreviewmag.com/2018/10/rhinomed-licensing-agreement-medical-cannabis-sleep/

The companies believe that nasally delivered, dose-metered, targeted medical cannabis formulations open up a new pathway and opportunity across a range of indications for this class of medication within the pharmaceutical and over-the-counter consumer health/wellness settings. The program will see Rhinomed’s platform used to develop a range of unique nasally delivered cannabinoid products “in a range of qualifying conditions and symptoms including obstructive sleep apnea, PTSD, pain relief, anti-nausea, and other sleep-related conditions,” states a press release.  (Melbourne, Australia)

Leave a Reply

Your email address will not be published.